- Home
- / Eloxx Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Eloxx Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$629
2024-10-29
CreditSafe Score
?
Score changed on Jun 16, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.0K | 182.2K | 75.0K | 75.0K | ||||||||
| General and administrative expense | 2.7M | 2.5M | 3.7M | 3.2M | 1.6M | 1.4M | 26.5M | 24.7M | 14.8M | 20.4M | 10.7M | 3.4M |
| Operating expense total | 5.3M | 4.6M | 7.0M | 7.7M | 3.8M | 2.1M | 47.0M | 50.6M | 29.4M | 34.4M | 6.4M | |
| EBIT | (5.1M) | (4.7M) | (9.1M) | (18.1M) | (11.2M) | (4.6M) | (47.6M) | (50.6M) | (33.5M) | (66.0M) | (34.4M) | (6.4M) |
| EBIT margin, % | -2545.2% | -5019.9% | -24102.3% | -14926.6% | ||||||||
| Interest income | 33.0K | |||||||||||
| Interest expense | 127.1K | 119.1K | 77.4K | 2.8K | 533.0 | 265.2K | 25.0K | |||||
| Pre tax profit | (8.9M) | (6.8M) | (47.1M) | (50.9M) | (34.6M) | (66.7M) | (36.1M) | (6.0M) | ||||
| Income tax expense | (680.0K) | (1.0M) | 122.0K | |||||||||
| Net Income | (5.1M) | (6.1M) | (9.2M) | (18.1M) | (8.3M) | (5.8M) | (47.2M) | (50.9M) | (34.6M) | (66.7M) | (36.1M) | (6.0M) |
| EPS | (16.6) | (0.5) |